首页> 外文期刊>International Journal of Clinical Oncology >A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib
【24h】

A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib

机译:舒尼替尼有效治疗转移性Xp11.2易位肾细胞癌的案例研究

获取原文
获取原文并翻译 | 示例
           

摘要

We report a case of Xp11.2 translocation renal cell carcinoma (RCC) whose lung metastases were effectively treated with sunitinib. A 43-year-old woman presenting with upper abdominal pain was diagnosed with a left renal tumor. Laparoscopic left radical nephrectomy was performed. Histopathological examination of the surgical specimen revealed a clear-cell carcinoma of the left kidney. Two years later, multiple lung metastases were detected and the patient was treated daily with 50 mg sunitinib. A computed tomography scan performed after 2 cycles of sunitinib treatment revealed partial regression of these metastases. The partial regression has been maintained for 3 years. In retrospective evaluation of the primary RCC, tumor cells showed strong nuclear staining for transcription factor E3 (TFE3) protein and TFE3 split-fluorescence in-situ hybridization revealed translocation involving the TFE3 gene. These findings strongly support diagnosis of Xp11.2 translocation RCC.
机译:我们报告Xp11.2易位肾细胞癌(RCC)的一例,其舒尼替尼有效治疗了肺转移。一名出现上腹部疼痛的43岁妇女被诊断出患有左肾肿瘤。进行腹腔镜左根切除术。手术标本的组织病理学检查显示左肾透明细胞癌。两年后,检测到多处肺转移,每天用50 mg舒尼替尼治疗该患者。在舒尼替尼治疗2个周期后进行的计算机断层扫描显示这些转移灶部分消退。局部回归已保持> 3年。在对原发性RCC的回顾性评估中,肿瘤细胞对转录因子E3(TFE3)蛋白显示出强核染色,并且TFE3拆分荧光原位杂交揭示了涉及TFE3基因的易位。这些发现强烈支持Xp11.2易位RCC的诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号